Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models

D. Betty Lew, Christie Michael, Tracie Overbeck, W. Scout Robinson, Erin L. Rohman, Jeffrey M. Lehman, Jennifer K. Patel, Brandi Eiseman, Kim S. Lemessurier, Amali Samarasinghe, M. Waleed Gaber

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.

Original languageEnglish (US)
Article number3432701
JournalJournal of Immunology Research
Volume2017
DOIs
StatePublished - Aug 1 2017

Fingerprint

Mannans
Prebiotics
Smooth Muscle
Saccharomyces cerevisiae
Asthma
Allergens
Smooth Muscle Myocytes
Anti-Inflammatory Agents
Hydrolases
Hypertrophy
Transgenic Mice
Hyperplasia
Cell Proliferation
Therapeutics
mannose receptor

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Lew, D. B., Michael, C., Overbeck, T., Robinson, W. S., Rohman, E. L., Lehman, J. M., ... Gaber, M. W. (2017). Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models. Journal of Immunology Research, 2017, [3432701]. https://doi.org/10.1155/2017/3432701

Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models. / Lew, D. Betty; Michael, Christie; Overbeck, Tracie; Robinson, W. Scout; Rohman, Erin L.; Lehman, Jeffrey M.; Patel, Jennifer K.; Eiseman, Brandi; Lemessurier, Kim S.; Samarasinghe, Amali; Gaber, M. Waleed.

In: Journal of Immunology Research, Vol. 2017, 3432701, 01.08.2017.

Research output: Contribution to journalArticle

Lew, DB, Michael, C, Overbeck, T, Robinson, WS, Rohman, EL, Lehman, JM, Patel, JK, Eiseman, B, Lemessurier, KS, Samarasinghe, A & Gaber, MW 2017, 'Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models', Journal of Immunology Research, vol. 2017, 3432701. https://doi.org/10.1155/2017/3432701
Lew, D. Betty ; Michael, Christie ; Overbeck, Tracie ; Robinson, W. Scout ; Rohman, Erin L. ; Lehman, Jeffrey M. ; Patel, Jennifer K. ; Eiseman, Brandi ; Lemessurier, Kim S. ; Samarasinghe, Amali ; Gaber, M. Waleed. / Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models. In: Journal of Immunology Research. 2017 ; Vol. 2017.
@article{48d4bef41e7c451390ad5782348b018f,
title = "Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models",
abstract = "One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.",
author = "Lew, {D. Betty} and Christie Michael and Tracie Overbeck and Robinson, {W. Scout} and Rohman, {Erin L.} and Lehman, {Jeffrey M.} and Patel, {Jennifer K.} and Brandi Eiseman and Lemessurier, {Kim S.} and Amali Samarasinghe and Gaber, {M. Waleed}",
year = "2017",
month = "8",
day = "1",
doi = "10.1155/2017/3432701",
language = "English (US)",
volume = "2017",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Beneficial effects of prebiotic saccharomyces cerevisiae mannan on allergic asthma mouse models

AU - Lew, D. Betty

AU - Michael, Christie

AU - Overbeck, Tracie

AU - Robinson, W. Scout

AU - Rohman, Erin L.

AU - Lehman, Jeffrey M.

AU - Patel, Jennifer K.

AU - Eiseman, Brandi

AU - Lemessurier, Kim S.

AU - Samarasinghe, Amali

AU - Gaber, M. Waleed

PY - 2017/8/1

Y1 - 2017/8/1

N2 - One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.

AB - One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.

UR - http://www.scopus.com/inward/record.url?scp=85032667894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032667894&partnerID=8YFLogxK

U2 - 10.1155/2017/3432701

DO - 10.1155/2017/3432701

M3 - Article

VL - 2017

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 3432701

ER -